CB-668

Finally, we tested IL4I1 expression in response to Fedratinib, a JAK2 inhibitor, and showed that IL4I1 expression was decreased in responders (R) vs nonresponders (NR) (Fig. 2F). We conclude that IL4I1 is a rational immune therapeutic target for AML and testing of IL4I1 Inhibitor CB-668 through a collaboration with Calithera is underway.

CB-668 also favorably combined with anti-PD-L1 therapy to reduce tumor growth in the B16-F10 tumor model. Conclusions These data support an immune-mediated anti-tumor effect of IL4I1 inhibition by CB-668, and suggest inhibition of IL4I1 represents a novel strategy for cancer immuno-therapy.

CB-668 also favorably combined with anti-PD-L1 therapy to reduce tumor growth in the B16-F10 tumor model. Conclusions These data support an immune-mediated anti-tumor effect of IL4I1 inhibition by CB-668, and suggest inhibition of IL4I1 represents a novel strategy for cancer immuno-therapy.